Document is current
Any future updates will be listed below
-
Authors
Karimzadeh, Amir
Hecker, Charlotte-Sophie
Heck, Matthias M.
Tauber, Robert
D’Alessandria, Calogero
Weber, Wolfgang A.
Eiber, Matthias
Rauscher, Isabel
-
Funding
Funding for this research was provided by:
Klinikum rechts der Isar der Technischen Universität München
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 23 August 2024
First Online: 14 October 2024
Declarations
:
: The institutional ethics committee of the Technical University of Munich approved this retrospective analysis under the reference number 115/18S. We certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.
: Not applicable.
: IR&ME report fees from Blue Earth Diagnostics Ltd. (consultant, research funding). IR is an Associate Editor of EJNMMI Research. ME reports fees from Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA<sup>®</sup>. RT: Advisory boards, speaking fees; travel support, conference access; author fees; shares: Astellas, AstraZeneca, Bayer, BMS, Eisai, EUSA, Ipsen, Janssen, Merck, MSD, Novartis, Orion, Philogen, Roche, Sanofi, Thieme. No other potential conflicts of interest relevant to this article exist.
